On Oct. 26, 2020, BioSig Technologies and its majority owned subsidiary, ViralClear Pharmaceuticals, announced the halting of its phase 2 trial, a randomized, double-blind, placebo-sontrolled study of the efficacy and safety of oal merimepodib in combination with intravenous remdesivir in adult patients with COVID-19.

Patients who were NIAID Grade 3 patients at the time of enrollment had markedly different outcomes that Grade 4 patients. Specifically, the unblinded SMC detected an imbalance in survival rates in these NIAID Grade 3 patients between the placebo and merimepodib making it unlikely that the trial would meet its primary safety endpoints.